Celcuity Inc. (CELC) Stock Price & Analysis
Celcuity Inc. (CELC) rose 5.90% to USD 92.59 as of June 10, 2026 at 00:49 UTC, according to Nexqual real-time market data.
CELC last closed at USD 87.43; the session ranged USD 87.77–94.32 on volume of 1,374,039 shares. Market capitalization is $4.52B, with a 52-week range of USD 11.28–151.02 (NCM). Source: Nexqual, June 10, 2026 at 00:49 UTC.
Key Statistics (as of June 10, 2026 at 00:49 UTC)
| Price | USD 92.59 |
|---|---|
| Change | ▲ 5.90% (up) |
| Previous Close | USD 87.43 |
| Open | USD 87.82 |
| Day Range | USD 87.77 – 94.32 |
| 52-Week Range | USD 11.28 – 151.02 |
| Volume | 1,374,039 shares |
| Market Cap | $4.52B |
| Exchange | NCM |
Technical Analysis (CELC)
Nexqual's technical model rates CELC "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.42 (neutral) |
| vs SMA50 | Below (USD 121.59) |
| MACD | -9.8 (negative) |
Analyst Ratings (CELC)
Wall Street analysts rate CELC "Strong Buy" based on 11 analysts, with a mean price target of USD 161.09 (range USD 145–175), per Nexqual as of June 10, 2026 at 00:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 161.09 |
| High Target | USD 175 |
| Low Target | USD 145 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (CELC)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.98 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.86 vs est -0.89 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -1.01 ▲ beat |
| 2025-09-30 | USD -0.78 vs est -0.96 ▲ beat |
| 2025-06-30 | USD -0.93 vs est -0.85 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:49 UTC.
Financials & Fundamentals (CELC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -275.17% |
| Debt / Equity | 604.28 |
| Current Ratio | 12.31 |
| Total Cash | $387.06M |
| Total Debt | $323.44M |
| Free Cash Flow | $-110.84M |
Source: Nexqual, June 10, 2026 at 00:49 UTC.
Financial Health Score (CELC)
Nexqual rates Celcuity Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $387M cash vs $323M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$172M |
| Efficiency | Critical — ROE -275%, ROA -37.1% |
Ownership (CELC)
| Insider Ownership | +10.01% |
|---|---|
| Institutional Ownership | +101.23% |
| Shares Outstanding | 48.77M |
| Float | 26.81M |
| Short % of Float | +29.45% |
Source: Nexqual, June 10, 2026 at 00:49 UTC.
Leadership (CELC)
Celcuity Inc. is led by Brian F. Sullivan (age 63), Co-Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 00:49 UTC.
| Co-Founder, Chairman & CEO | Brian F. Sullivan (age 63) |
|---|---|
| Co-Founder, Chief Science Officer, VP, Secretary & Director | Lance G. Laing (age 63) |
| Chief Financial Officer | Vicky Hahne (age 59) |
Major Backers & Investors (CELC)
Notable institutional backers of Celcuity Inc. include Baker Bros. Advisors, LP, Avoro Capital Advisors LLC, Perceptive Advisors Llc, according to Nexqual as of June 10, 2026 at 00:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 16.23% |
| Avoro Capital Advisors LLC | 6.92% |
| Perceptive Advisors Llc | 6.41% |
| RTW Investments LP | 6.23% |
| NEA Management Company, LLC | 4.69% |
| Deerfield Management Company, L.P | 3.51% |
| Morgan Stanley | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.81% |
| Vanguard Group | 7.23% |
| State Street | 4.79% |
Source: Nexqual, June 10, 2026 at 00:49 UTC.
From Celcuity Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- It is expected that approximately 200 clinical sites across North America, Europe, and Asia-Pacific will participate, including many sites included in the VIKTORIA-1 clinical trial.   In August 2025, the FDA granted our request to submit our NDA for gedatolisib under the FDA's Real-Time Oncology Review ("RTOR") program based on data from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial.
- We are also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, including a $5.0 million milestone payment we made in January 2026 following FDA acceptance of our NDA submission, up to an aggregate of $335.0 million.
- Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products.   There are several PI3K, AKT, and mTOR inhibitors approved by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca plc, ITOVEBI from F.
- We plan to protect our proprietary positions using a variety of methods, which include obtaining U.S. and foreign patents related to our inventions and improvements, and prosecuting additional U.S. and foreign patents that we determine are important to the development and implementation of our business.
Partnerships
- We also rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.       Gedatolisib Patents   We entered into the Gedatolisib License Agreement with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under Pfizer patents and know-how to develop, manufacture and commercialize gedatolisib.
- We may also elect to enter into agreements with other CMOs to formulate and manufacture supplies of drug substance and finished drug product.        Sales and Marketing   If any of our product candidates are approved, we intend to market and commercialize them in the U.S. and select international markets, either alone or in partnership with others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABVX | Abivax SA | USD 102.72 | ▲ 1.17% |
| PRAX | Praxis Precision Medicines, Inc | USD 250.33 | ▼ 1.44% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| REPL | Replimune Group, Inc. | USD 9.24 | ▼ 2.43% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:49 UTC. This page is informational and not investment advice.